TFTakaaki Furukawa

Takaaki Furukawa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Takaaki Furukawa has a total of 73 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Relative Dose Intensity and Outcomes in Elderly Patients With Resectable Pancreatic Cancer Receiving Neoadjuvant Chemotherapy

    by Tsuyoshi Takeda, Masato Ozaka, Takashi Sasaki, Yosuke Inoue, Tatsuki Hirai, Takafumi Mie, Takaaki Furukawa, Takeshi Okamoto, Yu Takahashi, Naoki Sasahira

    Background: Neoadjuvant chemotherapy (NAC) with gemcitabine and S‐1 (GS) is the standard regimen for resectable pancreatic cancer (PC) in Japan. However, its efficacy in elderly patients and those with impaired renal function remains unclear. Methods: We retrospectively analyzed patients with resectable PC who received NAC GS. Patients were classified as elderly (≥ 75 years) or non‐elderly (< 75 years). The primary endpoint was relative dose intensity (RDI) of NAC. Secondary endpoints included adverse events (AEs), perioperative outcomes, RDI of adjuvant chemotherapy (AC), recurrence‐free survival (RFS), and overall survival (OS). Results: A total of 185 patients were included (non‐elderly: 148, elderly: 37). Median creatinine clearance (CCr) was lower in elderly patients (64.2 vs. 84.5 mL/min, p < 0.001). Mean RDI of GS was significantly lower in elderly patients and those with CCr < 50 mL/min, particularly when both factors coexisted. Severe hematologic AEs were more frequent in these groups, though perioperative outcomes were similar. While initiation of AC was delayed and RDI of adjuvant S‐1 was lower in elderly patients, RFS and OS did not significantly differ between groups. Conclusions: NAC GS appears feasible in elderly patients with resectable PC, though caution is needed in those with impaired renal function.

  • Changing treatment outcomes in metastatic and recurrent pancreatic cancer: a real-world comparison before and after the availability of nanoliposomal irinotecan

    by Takafumi Mie, Masato Ozaka, Takeshi Okamoto, Keito Suzuki, Yoichiro Sato, Tatsuki Hirai, Yuri Maegawa, Jun Hamada, Takaaki Furukawa, Yukari Suzuki, et al.

    Background: While nanoliposomal irinotecan (nal-IRI) plus 5-fluorouracil and leucovorin (5-FU/LV) showed higher efficacy than 5-FU/LV in controlled settings, whether the availability of this regimen has truly improved real-world survival outcomes in unresectable pancreatic cancer remains unclear. Methods: We retrospectively analyzed consecutive patients with metastatic or recurrent pancreatic cancer, who received second-line chemotherapy after gemcitabine with nab-paclitaxel (GnP) between April 2015 and September 2024 at our hospital. The patients were divided into two cohorts: patients treated before (Group A) and after (Group B) the availability of nal-IRI plus 5-FU/LV in Japan. Time to treatment failure (TTF) of first-line GnP, overall survival (OS), and progression-free survival (PFS) were compared between groups. OS from the beginning of first-line treatment (OS-1) and from the beginning of second-line treatment (OS-2) were evaluated. Results: A total of 426 patients (Group A/B: 230/196) were included. Median TTF were comparable (6.4/6.6 months, P = .75). However, median second-line PFS and OS-2 were significantly longer in Group B (PFS: 3.0/4.8 months, P = .03; OS-2: 6.3/8.2 months, P = .047). Median OS-1 tended to be longer in Group B (13.9/17.2 months, P = .07). Multivariate analysis revealed that treatment after the introduction of nal-IRI plus 5-FU/LV was an independent prognostic factor for OS-2 (hazard ratio, 0.75; P < .01). Conclusion: The introduction of nal-IRI plus 5-FU/LV was associated with improved second-line treatment outcomes, providing a new combination regimen with acceptable toxicity in metastatic or recurrent pancreatic cancer.

  • Clinical predictors of KRAS mutation detection in liquid biopsies for pancreatic ductal adenocarcinoma

    by Takaaki Furukawa, Ippei Fukada, Naomi Hayashi, Takeshi Okamoto, Yoichiro Sato, Yuri Maegawa, Tatsuki Hirai, Takafumi Mie, Tsuyoshi Takeda, Takashi Sasaki, et al.


  • Bone loss, osteoporosis, and fractures in patients with resected pancreatic head cancer

    by Tsuyoshi Takeda, Takashi Sasaki, Yosuke Inoue, Takeshi Okamoto, Tatsuki Hirai, Takafumi Mie, Takaaki Furukawa, Yukari Suzuki, Masato Ozaka, Yu Takahashi, et al.


  • Open Access

    Outcomes of partially covered self-expandable metal stents with different uncovered lengths in endoscopic ultrasound-guided hepaticogastrostomy: a Japanese retrospective study

    by Takeshi Okamoto, Takashi Sasaki, Tsuyoshi Takeda, Tatsuki Hirai, Takahiro Ishitsuka, Manabu Yamada, Hiroki Nakagawa, Takafumi Mie, Takaaki Furukawa, Akiyoshi Kasuga, et al.

    Background/Aims: The optimal length of the uncovered portion of partially covered self-expandable metal stents (PCSEMSs) used in endoscopic ultrasound-guided hepaticogastrostomy (EUS-HGS) remains unclear. This study investigated the safety and efficacy of PCSEMSs with different uncovered lengths, with a focus on stent migration and time to recurrent biliary obstruction (RBO).Methods: Outcomes of patients undergoing EUS-HGS using PCSEMSs with 5-mm and 20-mm uncovered portions at our institution from January 2016 to December 2021 were compared.Results: Sixty-two patients underwent EUS-HGS using PCSEMS (5/20-mm uncovered portions: 32/30). Stent migration occurred only in the 5-mm group. There were no differences in RBO rates (28.1% vs. 40.0%) or median time to RBO (6.8 vs. 7.1 months) between the two groups. Median overall survival (OS) was longer in the 20-mm group (3.1 vs. 4.9 months, p=0.037) due to the higher number of patients that resumed chemotherapy after EUS-HGS (56.7% vs. 28.1%, p=0.029). Good performance status, absence of hepatic metastases, and chemotherapy after EUS-HGS were independent predictors of longer OS.Conclusions: No migration was observed in patients treated with PCSEMS with 20-mm uncovered portions. Patients treated with PCSEMS with 20-mm uncovered portions performed at least as well as those treated with 5-mm uncovered portions in all material respects.


  • Open Access

    Risk factors for recurrent stenosis after balloon dilation for benign hepaticojejunostomy anastomotic stricture

    by Takafumi Mie, Takashi Sasaki, Takeshi Okamoto, Tsuyoshi Takeda, Chinatsu Mori, Yuto Yamada, Takaaki Furukawa, Akiyoshi Kasuga, Masato Matsuyama, Masato Ozaka, et al.

    Background/Aims: Hepaticojejunostomy anastomotic stricture (HJAS) is a feared adverse event associated with hepatopancreatobiliary surgery. Although balloon dilation for benign HJAS during endoscopic retrograde cholangiopancreatography with balloon-assisted enteroscopy has been reported to be useful, the treatment strategy remains controversial. Therefore, we evaluated the outcomes and risk factors of recurrent stenosis after balloon dilation alone for benign HJAS.Methods: We retrospectively analyzed consecutive patients who underwent balloon-assisted enteroscopy–endoscopic retrograde cholangiopancreatography for benign HJAS at our institution between July 2014 and December 2020.Results: Forty-six patients were included, 16 of whom had recurrent HJAS after balloon dilation. The patency rates at 1 and 2 years after balloon dilation were 76.8% and 64.2%, respectively. Presence of a residual balloon notch during balloon dilation was an independent predictor of recurrence (hazard ratio, 2.80; 95% confidence interval, 1.01–7.78; p=0.048), whereas HJAS within postoperative 1 year tended to be associated with recurrence (hazard ratio, 2.43; 95% confidence interval, 0.85–6.89; p=0.096). The patency rates in patients without a residual balloon notch were 82.1% and 73.1% after 1 and 2 years, respectively.Conclusions: Balloon dilation alone may be a viable option for patients with benign HJAS without residual balloon notches on fluoroscopy.


  • Bone loss over time and risk of osteoporosis in advanced pancreatic cancer

    by Tsuyoshi Takeda, Takashi Sasaki, Takeshi Okamoto, Tatsuki Hirai, Takahiro Ishitsuka, Manabu Yamada, Hiroki Nakagawa, Takaaki Furukawa, Takafumi Mie, Akiyoshi Kasuga, et al.

    Background: Pancreatic cancer has a high risk of developing osteoporosis. However, the impact of osteoporosis has not been well-studied. This study aimed to evaluate bone loss over time and risk of osteoporosis in patients with advanced pancreatic cancer. Methods: We retrospectively examined consecutive patients with unresectable pancreatic cancer who had evaluable computed tomography before treatment and at 1-year follow-up. Bone mineral density at the first lumbar vertebra was measured on computed tomography, and osteoporosis was defined as bone mineral density < 135 Hounsfield units. The prevalence and risk factors for osteoporosis, changes in bone mineral density over time and incidence of bone fractures were analyzed. Results: Three hundred eighty patients were included. Osteoporosis was associated with older age, female sex, low body mass index and poor performance status at baseline. A consistent decrease in bone mineral density was observed over time regardless of age, sex or disease status, resulting in an increase in the prevalence of osteoporosis over time (47% at baseline, 79% at 1 year, 88% at 2 years, 89% at 3 years, 95% at 4 years and 100% at 5 years). Changes in bone mineral density from baseline were greater in patients with locally-advanced pancreatic cancer, in those who received modified FOLFIRINOX or S-IROX for more than 3 months, and in those who received radiation therapy. Incident fractures developed in 45 patients (12%) during follow-up. Conclusions: Osteoporosis and osteoporotic fractures were highly prevalent in patients with advanced pancreatic cancer. This study highlights the importance of screening for osteoporosis in such patients.


  • Open Access

    Current Status of Targeted Therapy for Biliary Tract Cancer in the Era of Precision Medicine

    by Takafumi Mie, Takashi Sasaki, Takeshi Okamoto, Takaaki Furukawa, Tsuyoshi Takeda, Akiyoshi Kasuga, Masato Ozaka, Naoki Sasahira

    First-line chemotherapy has been established for advanced biliary tract cancer (BTC). However, few treatment options are available as second-line treatment. Advances in comprehensive genomic analysis revealed that nearly half of patients with BTC harbor targetable genetic alterations such as fibroblast growth factor receptor (FGFR), isocitrate dehydrogenase (IDH), BRAF, human epidermal growth factor receptor 2 (HER2), microsatellite instability (MSI)-high, neurotrophic tropomyosin receptor kinase (NTRK), rearranged during transfection (RET), and poly (adenosine diphosphate-ribose) polymerase (PARP). This review summarizes currently available options in precision medicine and clinical trials for patients with advanced BTC.


  • Open Access

    Rotatable sphincterotome as a rescue device for endoscopic retrograde cholangiopancreatography cannulation: a single-center experience

    by Takeshi Okamoto, Takashi Sasaki, Tsuyoshi Takeda, Takafumi Mie, Chinatsu Mori, Takaaki Furukawa, Yuto Yamada, Akiyoshi Kasuga, Masato Matsuyama, Masato Ozaka, et al.

    Background/Aims: Selective bile duct or pancreatic duct cannulation remains a significant initial hurdle in endoscopic retrograde cholangiopancreatography (ERCP) despite advances in endoscopy and accessories. This study evaluated our experience with a rotatable sphincterotome in cases of difficult cannulation.Methods: We retrospectively reviewed ERCP cases using TRUEtome, a rotatable sphincterotome, as a rescue device for cannulation at a cancer institute in Japan from October 2014 to December 2021.Results: TRUEtome was used in 88 patients. Duodenoscopes were used for 51 patients, while single-balloon enteroscopes (SBE) were used for 37 patients. TRUEtome was used for biliary and pancreatic duct cannulation (84.1%), intrahepatic bile duct selection (12.5%), and strictures of the afferent limb (3.4%). Cannulation success rates were similar in the duodenoscope and SBE groups (86.3% vs. 75.7%, p=0.213). TRUEtome was more commonly used in cases with steep cannulation angles in the duodenoscope group and in cases requiring cannulation in different directions in the SBE group. There were no significant differences in adverse events between the two groups.Conclusions: The cannulation sphincterotome was useful for difficult cannulations in both unaltered and surgically altered anatomies. It may be an option to consider before high-risk procedures such as precut and endoscopic ultrasound-guided rendezvous techniques.


  • Open Access

    Splenic Hilar Involvement and Sinistral Portal Hypertension in Unresectable Pancreatic Tail Cancer

    by Takeshi Okamoto, Tsuyoshi Takeda, Takafumi Mie, Tatsuki Hirai, Takahiro Ishitsuka, Manabu Yamada, Hiroki Nakagawa, Takaaki Furukawa, Akiyoshi Kasuga, Takashi Sasaki, et al.

    Background: Pancreatic tail cancer (PTC) frequently displays splenic hilar involvement (SHI), but its impact on clinical outcomes remains unclear. We investigated the clinical impact of SHI in patients with unresectable PTC. Methods: We retrospectively reviewed all patients with unresectable PTC who received first-line therapy at our institution from 2016 to 2020. Results: Of the 111 included patients, 48 had SHI at diagnosis. SHI was significantly associated with younger age, liver metastasis, peritoneal dissemination, larger tumor size, modified Glasgow prognostic score of 1 or more, splenic artery involvement, gastric varices, and splenomegaly. Shorter median overall survival (OS; 9.3 vs. 11.6 months, p = 0.003) and progression-free survival (PFS; 4.3 vs. 6.3 months, p = 0.013) were observed in SHI patients. Poor performance status of 1 or 2, tumor size > 50 mm, hepatic metastasis, mGPS of 1 or 2, and SHI (hazard ratio: 1.65, 95% confidence interval: 1.08–2.52, p = 0.020) were independent predictors of shorter OS. Splenic artery pseudoaneurysm rupture and variceal rupture were rare and only observed in cases with SHI. Conclusions: Splenic hilar involvement is associated with worse outcomes in pancreatic tail cancer.